Product Description: Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC[1]) and urokinase-type plasminogen activator receptor (uTPA[2]). Amiloride is a blocker of polycystin-2 (PC2; TRPP2[3]) channel.
Applications: Metabolism-protein/nucleotide metabolism
Formula: C6H8ClN7O
Citations: ACS Nano. 2023 Apr 14./Adv Sci (Weinh). 2023 Dec 14:e2307880./Am J Transl Res. 2021 Jul 15;13(7):7538-7555./Cell Commun Signal. 2023 May 4;21(1):99./Cell Metab. 2022 Dec 6;34(12):2018-2035.e8./Cell Physiol Biochem. 2018;51(6):2564-2574. /Commun Biol. 2022 Nov 14;5(1):1248./Environ Sci Technol. 2021 Feb 11./J Am Chem Soc. 2018 Dec 12;140(49):17234-17240./J Nanobiotechnology. 2020 Jan 31;18(1):26./J Pharmaceut Biomed. 2020, 113870./Microb Pathog. 2019 Jul 18:103638. /Nanotechnology. 2018 Feb 23;29(8):085101./Small Methods. 2020 Dec 18./Theranostics. 2019 May 31;9(13):3732-3753./Biomaterials. 2022 May;284:121529./Br J Pharmacol. 2020 Aug;177(15):3473-3488. /Cell Rep. 2022 May 31;39(9):110880./Int J Biol Macromol. 14 March 2022./iScience. 19 October 2022, 105403./J Ethnopharmacol. 2022 Mar 5;115171./J Neuroinflammation. 2022 Feb 22;19(1):53./Sci Total Environ. 2021, 146523./Theranostics. 2020 May 17;10(15):6581-6598. /Transl Res. 2023 Sep 5;S1931-5244(23)00143-3.
References: [1]Giamarchi A, et al. A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J. 2010 Apr 7;29(7):1176-91./[2]Teiwes J, et al. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007 Jan;20(1):109-17./[3]Ji, H.L., et al. delta ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol, 2012. 303(12): p. L1013-26.
CAS Number: 2609-46-3
Molecular Weight: 229.63
Compound Purity: 99.96
Research Area: Metabolic Disease; Cardiovascular Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Apoptosis;Sodium Channel;TRP Channel
English
Deutsch
